Abstract:Key PointsBiopharmaceutical drugs such as antibodies, peptides and recombinant proteins have high specificity and potency compared to small molecules. These features arise from their macromolecular composition, which provides the structural complexity that is often required for specificity.However, this structural complexity means that biopharmaceutical drugs are large and susceptible to degradation, which makes it challenging to formulate and deliver them. These drugs also have reduced permeation across biological barriers, which complicates their delivery to specific sites or intracellular targets.In this Review we highlight recent advances in formulation and delivery strategies that have facilitated the transformation of product portfolios and development pipelines by this class of compounds. These advances include the use of microsphere-based sustained-release technologies, protein modification methods that make use of polyethylene glycol and other polymers, as well as genetic manipulation of biopharmaceutical drugs such as Fc- and albumin-fusions.We also highlight current and emerging delivery routes that provide alternatives to injection, including transdermal, oral and pulmonary delivery.Current areas of formulation and delivery research show promise for the application of biopharmaceutical drugs to tumour immunotherapy using nanoparticle technology, tissue engineering and enhanced approaches to cell-based therapy.These delivery methods could be used for the targeted delivery of proteins to the brain, which could have implications in the treatment of a wide range of central nervous system disorders. These technologies could potentially increase the effectiveness of conventional approaches that have not yet translated to the clinic, although they have had promising preclinical results.Intracellular delivery of proteins and peptides is a new frontier in delivery research, which could dramatically augment the breadth of targets amenable to biopharmaceutical drug therapy.

Albumin-based drug delivery: harnessing nature to cure disease

Albumin nanoscience: homing nanotechnology enabling targeted drug delivery and therapy

Albumin as Drug Carriers

Albumin-based potential drugs: focus on half-life extension and nanoparticle preparation

Harnessing albumin as a carrier for cancer therapies

Albumin-binding as a universal strategy for half-life extension

Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation

Simple bioconjugate chemistry serves great clinical advances: albumin as a versatile platform for diagnosis and precision therapy.

Inflammation-Targeted Drug Delivery Strategies via Albumin-Based Systems

Human serum albumin binders: A piggyback ride for long-acting therapeutics

Recent Advances on the Development of Pharmacotherapeutic Agents on the Basis of Human Serum Albumin

Application of Albumin in Drugs Delivery System

Recombinant Human Serum Albumin Fusion Proteins and Novel Applications in Drug Delivery and Therapy

An Albumin Sandwich Enhances in Vivo Circulation and Stability of Metabolically Labile Peptides

Recent Advancements in Erythrocytes, Platelets, and Albumin As Delivery Systems

Natural and Synthetic Polymers As Drug Carriers for Delivery of Therapeutic Proteins

The Neoteric Paradigm of Biomolecule-Functionalized Albumin-Based Targeted Cancer Therapeutics

Application of Albumin in Nanodrugs for Cancer Therapy

Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies

Research progress of serum albumin in the field of drug delivery

Protein Nanoparticles: Promising Platforms for Drug Delivery Applications